Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
1.
BMC Genomics ; 25(1): 417, 2024 Apr 27.
Artículo en Inglés | MEDLINE | ID: mdl-38678201

RESUMEN

BACKGROUND: Between 2020 and 2022, eight calves in a Nebraska herd (composite Simmental, Red Angus, Gelbvieh) displayed exercise intolerance during forced activity. In some cases, the calves collapsed and did not recover. Available sire pedigrees contained a paternal ancestor within 2-4 generations in all affected calves. Pedigrees of the calves' dams were unavailable, however, the cows were ranch-raised and retained from prior breeding seasons, where bulls used for breeding occasionally had a common ancestor. Therefore, it was hypothesized that a de novo autosomal recessive variant was causative of exercise intolerance in these calves. RESULTS: A genome-wide association analysis utilizing SNP data from 6 affected calves and 715 herd mates, followed by whole-genome sequencing of 2 affected calves led to the identification of a variant in the gene PYGM (BTA29:g.42989581G > A). The variant, confirmed to be present in the skeletal muscle transcriptome, was predicted to produce a premature stop codon (p.Arg650*). The protein product of PYGM, myophosphorylase, breaks down glycogen in skeletal muscle. Glycogen concentrations were fluorometrically assayed as glucose residues demonstrating significantly elevated glycogen concentrations in affected calves compared to cattle carrying the variant and to wild-type controls. The absence of the PYGM protein product in skeletal muscle was confirmed by immunohistochemistry and label-free quantitative proteomics analysis; muscle degeneration was confirmed in biopsy and necropsy samples. Elevated skeletal muscle glycogen persisted after harvest, resulting in a high pH and dark-cutting beef, which is negatively perceived by consumers and results in an economic loss to the industry. Carriers of the variant did not exhibit differences in meat quality or any measures of animal well-being. CONCLUSIONS: Myophosphorylase deficiency poses welfare concerns for affected animals and negatively impacts the final product. The association of the recessive genotype with dark-cutting beef further demonstrates the importance of genetics to not only animal health but to the quality of their product. Although cattle heterozygous for the variant may not immediately affect the beef industry, identifying carriers will enable selection and breeding strategies to prevent the production of affected calves.


Asunto(s)
Estudio de Asociación del Genoma Completo , Glucógeno Fosforilasa de Forma Muscular , Animales , Bovinos , Femenino , Masculino , Enfermedades de los Bovinos/genética , Genes Recesivos , Glucógeno Fosforilasa de Forma Muscular/genética , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Linaje , Polimorfismo de Nucleótido Simple , Secuenciación Completa del Genoma
2.
Physiol Genomics ; 48(2): 93-100, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26465709

RESUMEN

McArdle disease (glycogen storage disease type V) is caused by inherited deficiency of a key enzyme in muscle metabolism, the skeletal muscle-specific isoform of glycogen phosphorylase, "myophosphorylase," which is encoded by the PYGM gene. Here we review the main pathophysiological, genotypic, and phenotypic features of McArdle disease and their interactions. To date, moderate-intensity exercise (together with pre-exercise carbohydrate ingestion) is the only treatment option that has proven useful for these patients. Furthermore, regular physical activity attenuates the clinical severity of McArdle disease. This is quite remarkable for a monogenic disorder that consistently leads to the same metabolic defect at the muscle tissue level, that is, complete inability to use muscle glycogen stores. Further knowledge of this disorder would help patients and enhance understanding of exercise metabolism as well as exercise genomics. Indeed, McArdle disease is a paradigm of human exercise intolerance and PYGM genotyping should be included in the genetic analyses that might be applied in the coming personalized exercise medicine as well as in future research on genetics and exercise-related phenotypes.


Asunto(s)
Tolerancia al Ejercicio/genética , Ejercicio Físico , Enfermedad del Almacenamiento de Glucógeno Tipo V/genética , Enfermedad del Almacenamiento de Glucógeno Tipo V/fisiopatología , Adolescente , Adulto , Biopsia , Femenino , Genotipo , Glucógeno/metabolismo , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Glucógeno Fosforilasa de Forma Muscular/genética , Enfermedad del Almacenamiento de Glucógeno Tipo V/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Músculo Esquelético/metabolismo , Músculos/metabolismo , Mutación , Fenotipo , Sistema de Registros , España
3.
J Inherit Metab Dis ; 38(2): 221-30, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25053163

RESUMEN

Numerous biomedical advances have been made since Carl and Gerty Cori discovered the enzyme phosphorylase in the 1940s and the Scottish physician Brian McArdle reported in 1951 a previously 'undescribed disorder characterized by a gross failure of the breakdown in muscle of glycogen'. Today we know that this disorder, commonly known as 'McArdle disease', is caused by inherited deficiency of the muscle isoform of glycogen phosphorylase (GP). Here we review the main aspects of the 'pathogenomics' of this disease including, among others: the spectrum of mutations in the gene (PYGM) encoding muscle GP; the interplay between the different tissue GP isoforms in cellular cultures and in patients; what can we learn from naturally occurring and recently laboratory-generated animal models of the disease; and potential therapies.


Asunto(s)
Glucógeno Fosforilasa de Forma Muscular/genética , Enfermedad del Almacenamiento de Glucógeno Tipo V/genética , Músculo Esquelético/enzimología , Mutación , Animales , Análisis Mutacional de ADN , Modelos Animales de Enfermedad , Tolerancia al Ejercicio , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Enfermedad del Almacenamiento de Glucógeno Tipo V/enzimología , Enfermedad del Almacenamiento de Glucógeno Tipo V/fisiopatología , Enfermedad del Almacenamiento de Glucógeno Tipo V/terapia , Humanos , Ratones Transgénicos , Músculo Esquelético/fisiopatología , Fenotipo , Valor Predictivo de las Pruebas , Pronóstico
4.
Mol Genet Metab ; 104(4): 587-91, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21880526

RESUMEN

McArdle disease is an autosomal recessive glycogenosis due to deficiency of the enzyme myophosphorylase. It results from homozygous or compound heterozygous mutations in the gene for this enzyme, PYGM. We report six novel mutations in the PYGM gene based upon sequencing data including three missense mutations (p.D51G, p.P398L, and p.N648Y), one nonsense mutation (p.Y75X), one frame-shift mutation (p.Y114SfsX181), and one amino acid deletion (p.Y53del) in six patients with McArdle disease. We also report on a Caucasian family that appeared to transmit McArdle disease in an autosomal dominant manner. In order to evaluate the potential pathogenicity of the sequence variants, we performed in silico analysis using PolyPhen-2 and SIFT BLink, along with species conservation analysis using UCSC Genome Browser. The above mutations were all predicted to be disease associated with high probability and with at least the same level of certainty as several confirmed mutations. The current data add to the list of pathogenic mutations in the PYGM gene associated with McArdle disease.


Asunto(s)
Genes Dominantes , Glucógeno Fosforilasa de Forma Muscular/genética , Enfermedad del Almacenamiento de Glucógeno Tipo V/genética , Mutación , Adolescente , Adulto , Secuencia de Aminoácidos , Niño , Simulación por Computador , Secuencia Conservada , Análisis Mutacional de ADN , Femenino , Estudios de Asociación Genética , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Enfermedad del Almacenamiento de Glucógeno Tipo V/enzimología , Haplotipos , Humanos , Masculino , Persona de Mediana Edad , Modelos Moleculares , Adulto Joven
5.
Brain ; 132(Pt 6): 1545-52, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19433441

RESUMEN

Over 100 mutations in the myophosphorylase gene, which cause McArdle disease, are known. All these mutations have resulted in a complete block of muscle glycogenolysis, and accordingly, no genotype-phenotype correlation has been identified in this condition. We evaluated physiologic and genetic features of two patients with a variant form of McArdle disease, associated with unusually high exercise capacity. Physiologic findings were compared to those in 47 patients with typical McArdle disease, and 17 healthy subjects. Subjects performed an ischaemic forearm exercise test to assess lactate and ammonia production. Peak oxidative capacity (VO2max) and cardiac output were determined, using cycle ergometry as the exercise modality. The two patients with atypical McArdle disease carried common mutations on one allele (R50X and G205S), and novel splice mutations in introns 3 [IVS3-26A>G (c.425-26A>G)] and 5 [IVS5-601G>A (c.856-601G>A)] on the other allele. Plasma lactate after ischaemic exercise decreased in all typical McArdle patients, but increased in the two atypical McArdle patients (10% of that in healthy subjects). Peak workload and oxidative capacity were 2-fold higher in patients with atypical McArdle disease compared to typical McArdle patients. Oxygen uptake, relative to cardiac output, was severely impaired in the 47 patients with typical McArdle disease, and partially normalized in the milder affected McArdle patients. These findings identify the first distinct genotype-phenotype relationship in McArdle disease, and indicate that minimal myophosphorylase activity ameliorates the typical McArdle disease phenotype by augmenting muscle oxidative capacity. The milder form of McArdle disease provides important clues to the level of functional myophosphorylase needed to support muscle oxidative metabolism.


Asunto(s)
Glucógeno Fosforilasa de Forma Muscular/genética , Enfermedad del Almacenamiento de Glucógeno Tipo V/genética , Mutación , Adulto , Gasto Cardíaco/fisiología , Prueba de Esfuerzo/métodos , Femenino , Antebrazo/fisiopatología , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Glucógeno Fosforilasa de Forma Muscular/metabolismo , Enfermedad del Almacenamiento de Glucógeno Tipo V/enzimología , Enfermedad del Almacenamiento de Glucógeno Tipo V/fisiopatología , Humanos , Ácido Láctico/sangre , Masculino , Músculo Esquelético/enzimología , Consumo de Oxígeno/fisiología , Fenotipo , Sitios de Empalme de ARN/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos
6.
Nefrologia ; 29(1): 77-80, 2009.
Artículo en Español | MEDLINE | ID: mdl-19240776

RESUMEN

Rhabdomyolysis is a syndrome characterized by injure of skeletal muscle with the release of intracellular constituents into the circulation. Acute renal failure is a common complication and is the leading cause of morbidity and mortality in these patients. The most common aetiology is traumatisms, muscle compressions and extreme exertions. Most commonly, the cause of rhabdomyolysis is evident from the careful clinical history. Nevertheless, when the precipitant is not obvious the diagnosis is difficult and a raised clinical suspicion is required. We should investigate used medication or drugs, infections, electrolyte abnormalities and a number of inherited enzyme deficiencies, in which cases the muscle is unable to use available energy. We report two clinical cases of acute renal failure due to rhabdomyolysis by metabolic myopathies due to a carnitine palmitoyltransferase deficiency on the one hand and by myophosphorylase deficiency on the other. We describe their clinical features and progress.


Asunto(s)
Carnitina O-Palmitoiltransferasa/deficiencia , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Rabdomiólisis/etiología , Lesión Renal Aguda/etiología , Adulto , Humanos , Masculino , Rabdomiólisis/complicaciones
7.
J Vet Diagn Invest ; 18(2): 195-7, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16617701

RESUMEN

Improvements to restriction fragment length polymorphism (RFLP)-based genotyping assays currently used for detection of mutations responsible for bovine ferrochelatase and myophosphorylase deficiencies, and equine hyperkalemic periodic paralysis (HYPP) are described. Reports of sporadic inhibition of restriction enzyme activity suggest a critical factor in RFLP-based genotyping assays should be assurance that restriction enzymes perform to specification with every sample. The RFLP genotyping assays that use either a mismatched recognition sequence in one or both of the oligonucleotides, or incorporate a second native site within the PCR amplicon, provide the mechanism by which efficiency of restriction enzymes can be assessed with every sample. The outcome is confirmation of the activity of the discriminating enzyme regardless of genotype.


Asunto(s)
Enfermedades de los Bovinos/genética , Enfermedad del Almacenamiento de Glucógeno Tipo V/veterinaria , Enfermedades de los Caballos/genética , Parálisis Periódica Hiperpotasémica/veterinaria , Polimorfismo de Longitud del Fragmento de Restricción , Protoporfiria Eritropoyética/veterinaria , Animales , Bovinos , Enfermedades de los Bovinos/diagnóstico , Enfermedades de los Bovinos/enzimología , ADN/química , ADN/genética , Femenino , Ferroquelatasa/genética , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Glucógeno Fosforilasa de Forma Muscular/genética , Enfermedad del Almacenamiento de Glucógeno Tipo V/diagnóstico , Enfermedad del Almacenamiento de Glucógeno Tipo V/genética , Enfermedades de los Caballos/diagnóstico , Caballos , Masculino , Parálisis Periódica Hiperpotasémica/diagnóstico , Parálisis Periódica Hiperpotasémica/genética , Reacción en Cadena de la Polimerasa/métodos , Reacción en Cadena de la Polimerasa/veterinaria , Protoporfiria Eritropoyética/diagnóstico , Protoporfiria Eritropoyética/genética , Canales de Sodio/genética
8.
Arch Neurol ; 62(9): 1440-3, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16157752

RESUMEN

BACKGROUND: Muscle phosphoglycerate mutase deficiency (PGAMD) is a rare, recessively inherited metabolic myopathy that affects one of the last steps of glycolysis. Clinically, PGAMD resembles muscle phosphorylase deficiency (McArdle disease) and phosphofructokinase deficiency (PFKD). However, it is unknown whether PGAMD is associated with a second-wind phenomenon during exercise, as in McArdle disease, and whether patients with PGAMD, like patients with PFKD and McArdle disease, benefit from supplementation with fuels that bypass the metabolic block. OBJECTIVE: To investigate whether fuels that bypass the metabolic block can improve exercise capacity or whether exercise capacity improves during sustained exercise. DESIGN: Single-blind, placebo-controlled investigation of the effects of glucose, lactate, and intralipid on work capacity in patients with PGAMD. SETTING: National University Hospital, University of Copenhagen, and Neuromuscular Center, Institute for Exercise and Environmental Medicine. Patients Two unrelated men (21 and 26 years old) with PGAMD who since their teens had experienced muscle cramps, muscle pain, and episodes of myoglobinuria provoked by brief vigorous exercise, 4 patients with McArdle disease (mean +/- SD age, 32 +/- 5 years) with 0% residual phosphorylase activity in muscle, and 6 healthy, untrained male volunteers (mean +/- SD age, 23 +/- 1 years) were studied. INTERVENTIONS: Using constant and variable workload protocols on a cycle ergometer, it was investigated whether a spontaneous second wind occurs during exercise in patients with PGAMD, and using a constant workload protocol followed by an incremental load to exhaustion, it was tested whether infusion of lactate, glucose, or intralipid alters the exercise tolerance in PGAMD. MAIN OUTCOME MEASURES: Whether a second wind occurs during exercise and whether fuels that bypass the metabolic block can improve exercise and oxidative capacity. RESULTS: In contrast to patients with McArdle disease, with whom they share many clinical features, in patients with PGAMD, cycle exercise and oxidative capacity are virtually normal, a second wind does not occur, and lipid and lactate supplements do not improve exercise capacity. CONCLUSION: Although the clinical manifestations of PGAMD mimic McArdle disease with respect to the presence of exertional muscle cramps, rhabdomyolysis, and myoglobinuria, this study shows that cycle exercise responses are strikingly different.


Asunto(s)
Ejercicio Físico , Glucosa/administración & dosificación , Lactasa/administración & dosificación , Músculo Esquelético/efectos de los fármacos , Fosfoglicerato Mutasa/deficiencia , Adulto , Prueba de Esfuerzo/métodos , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Humanos , Espectroscopía de Resonancia Magnética/métodos , Masculino , Músculo Esquelético/enzimología , Músculo Esquelético/patología , Método Simple Ciego , Factores de Tiempo , Resultado del Tratamiento
9.
Arch Neurol ; 59(9): 1395-402, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12223025

RESUMEN

BACKGROUND: Blocked glycogen breakdown in McArdle disease impairs oxidative as well as anaerobic metabolism, but the contribution of impaired oxidative phosphorylation to everyday symptoms of McArdle disease remains poorly defined. OBJECTIVE: To evaluate the oxidative implications of the spontaneous second wind and variables that influence the development of this typical feature of McArdle disease. DESIGN: Assessment of exercise and oxidative capacity (.VO(2)) before and after the spontaneous "second wind" and with a glucose infusion after a spontaneous second wind. PATIENTS: Eight patients with complete myophosphorylase deficiency and 1 unique patient with 3% of normal myophosphorylase activity. MAIN OUTCOME MEASURES: Work capacity,.VO(2), heart rate, cardiac output. RESULTS: All patients with complete myophosphorylase deficiency (1) had low peak.VO(2) (mean +/- SD, 13.0 +/- 2.0 mL. kg(-1). min(-1)) in the first 6 to 8 minutes of exercise; (2) achieved a spontaneous second wind with increased exercise capacity between 8 and 12 minutes of exercise due to a more than 25% increase in peak.VO(2) (16.5 +/- 3.1 mL. kg(-1). min(-1)); and (3) with glucose infusion after a spontaneous second wind, experienced a further more than 20% increase in oxidative capacity (.VO(2), 19.9 +/- 3.9 mL. kg(-1). min(-1)). In the patient with residual myophosphorylase,.VO(2) (22.2 mL. kg(-1). min(-1)) in the first 6 to 8 minutes of exercise was approximately 2-fold higher than the mean of patients lacking myophosphorylase, and no significant improvement in exercise and oxidative capacity accompanied prolonged exercise or glucose infusion. CONCLUSIONS: First, the spontaneous second wind and the glucose-induced second second wind in McArdle disease are due to substrate-dependent increases in muscle oxidative capacity. Second, by providing glycogen-derived pyruvate, a small amount of residual myophosphorylase activity normalizes the oxidative deficit of complete myophosphorylase deficiency and virtually eliminates the spontaneous second wind and glucose-induced second second wind.


Asunto(s)
Glucosa/farmacología , Enfermedad del Almacenamiento de Glucógeno Tipo V/metabolismo , Adulto , Umbral Anaerobio/fisiología , Gasto Cardíaco/fisiología , Ejercicio Físico/fisiología , Femenino , Glucógeno Fosforilasa de Forma Muscular/deficiencia , Frecuencia Cardíaca/fisiología , Humanos , Ácido Láctico/sangre , Masculino , Oxidación-Reducción , Oxígeno/sangre , Consumo de Oxígeno/fisiología , Evaluación de Capacidad de Trabajo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda